ACT News 210.67 06/12/2014 04:22:37 Actavis Inc (ACT)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Actavis Inc (ACT) 210.67 $ACT

Worldwide IV Iron Drugs Industry Analysis and 2018 Forecasts New Research Study Available at MarketReportsOnline.com
PRWeb - 18 mins ago
Intravenous (IV) treatment, in a broad sense, covers all the types of medications delivered intravenously, i.e. directly into the vein, through intravenous drip. Compared to the other routes of infusing medications, the intravenous route is the fastest way to deliver fluids and medications throughout the body. Also, this method ensures 100% bioavailability, which means that the chemicals delivered are fully absorbed by the body. The first iron product for intravenous use was high-molecular-weight iron dextran. Some of the major areas of IV iron application include gynecology, gastroenterology, oncology and surgeries. Hemoglobin, Ferritin, Transferrin, and Hepcidin are major molecules which are critical in the function and regulation of iron.

Today's Top Performers In Health Care
at The Street - Wed Jun 11, 12:03PM CDT
TheStreet highlights 3 stocks pushing the health care sector higher today.

Actavis to close USD3.7bn senior unsecured notes on 19 June 2014
M2 - Wed Jun 11, 4:51AM CDT
Pharmaceutical company Actavis (NYSE:ACT) said on Tuesday that its Actavis Funding SCS indirect subsidiary has priced its total aggregate offering of USD3.7bn senior unsecured notes 19 June 2014.

Actavis, BitAuto Among Leading World Stocks In Bases
at Investor's Business Daily - Tue Jun 10, 5:50PM CDT
Six of the 10 stocks listed on the Top World Stocks list in Tuesday's IBD are pecking away at new highs. Some are still in buying range after clearing bases. Four others are building bases. One minor catch: They are all late-stage patterns. Late...

Actavis Prices $3.7 Billion of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 4:19PM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, priced a private debt offering of $500 million of 1.300% senior unsecured notes due 2017, $500 million of 2.450% senior unsecured notes due 2019, $1.2 billion of 3.850% senior unsecured notes due 2024 and $1.5 billion of 4.850% senior unsecured notes due 2044, for a total offering of $3.7 billion in aggregate principal amount. The offering is expected to close on June 19, 2014, subject to market conditions and other factors.

Lannett In Buying Range After Breakout From Cup Base
at Investor's Business Daily - Tue Jun 10, 3:35PM CDT
Generic-drug maker Lannett (LCI) is in buying range following a breakout from a cup-without-handle base. The stock is within the 5% buy area after succeeding Monday in its third try to clear the 46.61 buy point. The previous attempts last Thursday...

Fitch Rates New Actavis Bonds 'BBB-'; Outlook Stable
Business Wire - Tue Jun 10, 9:55AM CDT
Fitch Ratings has assigned a 'BBB-' rating to new senior unsecured bonds to be issued by an indirect subsidiary of Actavis plc (NYSE: ACT). Fitch has also assigned a 'BBB-' Issuer Default Rating (IDR) to Actavis Funding SCS, the issuer of the bonds, and Warner Chilcott Limited. ACT's IDR is 'BBB-', with a Stable Outlook. A full list of ratings for ACT follows at the end of this release.

Actavis Announces Offering of Senior Unsecured Notes
PR Newswire - Tue Jun 10, 7:48AM CDT
Actavis plc (NYSE: ACT) today announced that its indirect subsidiary, Actavis Funding SCS, is privately offering three, five, ten and thirty year senior unsecured notes.

Actavis Finalizes Agreement Related to Asacol® HD Patent Challenge Litigation
PR Newswire - Mon Jun 09, 4:54PM CDT
Actavis plc (NYSE: ACT) today announced that it has finalized its previously announced agreement with Zydus Pharmaceuticals USA Inc. to settle all outstanding patent litigation related to Zydus' generic version of Asacol® HD (mesalamine) delayed-release tablets. The terms of the agreement are unchanged from those disclosed by the companies in December 2013.

Why I Like Actavis Stock
Mohsin Saeed, The Motley Fool - Motley Fool - Mon Jun 09, 1:12PM CDT
Investments in small capitalization biotechnology companies are fraught with risks. Most bio-techs rely on a single or a few trial candidates to determine their entire valuations. With little or no revenues, the downside to these stocks is immense. A...

Forest Laboratories, Inc. Extends Expiration Time of Consent Solicitations to Eliminate Existing Registration Rights Obligations on Certain of its Senior Notes
Business Wire - Mon Jun 09, 7:01AM CDT
Forest Laboratories, Inc. (NYSE:FRX) today announced that it has extended the expiration date of its consent solicitations (the "Consent Solicitations" to eliminate existing registration rights obligations with respect to its outstanding debt securities listed in the table below (the "FRX Notes" in exchange for the offer by Actavis plc (NYSE: ACT) to guarantee (the "ACT Guarantees" each of the FRX Notes. The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Actavis Extends Expiration Time of Offer to Guarantee Certain Forest Laboratories Senior Notes in Connection with Forest Consent Solicitations
PR Newswire - Mon Jun 09, 7:00AM CDT
Actavis plc (NYSE: ACT) (the "Company" today announced that it has extended the expiration date of its offer to guarantee the outstanding debt securities listed in the table below (the "FRX Notes" of Forest Laboratories, Inc. (NYSE: FRX) in exchange for the elimination of the existing registration rights obligations with respect to each of those debt securities (the "Consent Solicitations" . The Consent Solicitations were originally scheduled to expire at 5:00 p.m., New York City time, on June 6, 2014. The expiration date of the Consent Solicitations has been extended until 5:00 p.m., New York City time, on June 12, 2014.

Several IBD 50 Names Set Up In Stock Picker's Market
at Investor's Business Daily - Fri Jun 06, 4:58PM CDT
A nascent market uptrend, confirmed by the Nasdaq and S&P 500 on May 27, is looking pretty good. Distribution days, or higher-volume declines, have been nonexistent so far and growth stocks overall are holding up well. The IBD 50 is essentially flat...

The World Market for Biosimilars 2013-2017 - EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies
M2 - Fri Jun 06, 8:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/7brbq6/the_world_market) has announced the addition of the "The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other), 4th Edition" report to their offering. The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others), is designed to provide a comprehensive look at the various strategies being used by select worldwide generic companies in exploring the emerging area of biosimilars, the issues and trends that are shaping the marketplace, and the potential feasibility of providing biosimilars within the United States regulatory environment. Generic drugs continue to represent one of the greatest values in healthcare and are of great importance in the area of biopharmaceuticals as well because these products are among the most expensive treatments currently on the market. Generic drug manufacturers are poised for strong growth in the future because the patent protection for a host of major biopharmaceuticals will expire and new legislative reforms in the generic drug approval process may facilitate bringing products to market. While there are many issues to address, the outlook for biosimilar promotion is favorable in the next five years. As part of its coverage, the report provides the following: - Scientific Differences of Pharmaceuticals and Biopharmaceuticals - Market Share of Biosimilar Sales in Comparison to Brand Sales - Marketed Biologics with Expired Patents - Marketed Biologics with Active Patents - Cost Savings From Biosimilar Use - World Biosimilar Market Potential by Region 2010-2017 - World Biosimilar Market Potential by Biological Class 2010-2017 ( EPO, G-CSF, HGH, Insulin, Interferon Alpha, Monoclonal Antibodies, Other) - Biosimilars Pipeline by Company and Product Type As part of its coverage, the following companies were profiled: - 3SBio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Bio Sidus S.A. - BioXpress Therapeutics S.A. - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy's Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals USA, - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance GeneMedix PLC - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International GmbH - STADA Arzneimittel AG - TEVA Pharmaceutical Industries, Ltd. - Wockhardt Ltd. - Xiamen Amoytop Biotech Co Ltd. For more information visit http://www.researchandmarkets.com/research/7b...rld_market

More Stock Leaders Emerge From More Industry Groups
at Investor's Business Daily - Thu Jun 05, 5:03PM CDT
The set of 16 charts on IBD Stock Spotlight's computer-run screen are showing two promising new trends. The first trend: Since the Nasdaq's May 27 confirmation of a new market uptrend, more stocks are hitting proper buy points, while others are...

Chicago sues painkiller firms
at Investor's Business Daily - Tue Jun 03, 5:56PM CDT
Following the lead of Calif.'s Orange and Santa Clara counties, Chicago is suing 5 drugmakers, alleging their marketing downplayed the risk of FDA-approved opioids in treating chronic pain. The city wants to recover profits, along with civil...

Top New Buys: Funds Pile Into Actavis, chip stocks
at Investor's Business Daily - Tue Jun 03, 5:35PM CDT
After a three-month-long correction, the Nasdaq composite index followed through on March 27. That means it's time to look for stocks breaking out of sound bases. But mutual funds have already been busy in recent months, their buying helping to form...

Health Care Sector Equities Scrutiny -- Research on AVANIR Pharma, Zoetis, Actavis, and Mallinckrodt
PR Newswire - Tue Jun 03, 6:50AM CDT
On Monday, June 2, 2014, the NASDAQ Composite ended at 4,237.20, down 0.13%, the Dow Jones Industrial Average edged 0.16% higher to finish the day at 16,743.63, and the S&P 500 closed at 1,924.97, up 0.07%. During the session gains in the Materials, Industrials, and Consumer Discretionary sectors positively impacted the broader market, while some retraction came in from Consumer Staples, Energy, and Information Technology sectors. The S&P 500 Health Care Sector Index ended the day at 691.40, up 0.17%, with the index advancing 3.37% in the last one month. Investor-Edge has initiated coverage on the following equities: AVANIR Pharmaceuticals Inc. (NASDAQ: AVNR), Zoetis Inc. (NYSE: ZTS), Actavis PLC (NYSE: ACT) and Mallinckrodt PLC (NYSE: MNK). Free technical research on AVNR, ZTS, ACT and MNK can be downloaded upon signing up at:

Actavis Acquires Forest Labs For Brand-Name Drugs
at Investor's Business Daily - Mon Jun 02, 5:03PM CDT
Large-cap drugmaker Actavis is looking to acquisitions to expand beyond the generics domain and into the branded prescription-drug realm on the heels of strong profit gains. Actavis' (ACT) first-quarter adjusted earnings soared 75% from a year...

New Employers Listed For Annual Life Science Hiring Event
PR Newswire - Mon Jun 02, 9:45AM CDT
HireLifeScience.com, the premier career networking website for the Life Science industries, will host its 5th annual career fair at The NJ Convention and Exposition Center at Raritan Center in Edison, NJ on September 30, 2014. The annual hiring event is being sponsored by Novo Nordisk. Additional event sponsors thus far include Covance and top generic drug company, Actavis, Inc. In addition to returning companies such as Johnson & Johnson, LifeCell and Cubist Pharmaceuticals there have been many companies added since April. Recent additions to the exhibitor list are Daiichi Sankyo, Musculoskeletal Transplant Foundation (MTF), DSM Nutritional Products, Acorda Therapeutics, GE Healthcare, Amneal Pharmaceuticals and Actavis, Inc. More companies will be added during the upcoming summer months creating the largest Life Science career fair for 2014 in the Tri-State area.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 124

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 7

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 415

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 324

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Thunes Boosts Bhutan Remittances with Instant Payments

Updated Category News Views 136

Thunes' Network Expands to Bhutan: A Game Changer I'll say one thing clear—Thunes isn't messing around. They've just opened the gates for real-time payouts to Bhutan, and it's going to be a game-changer for those living abroad who want to send money back home. Look, for years, Non-Resident Bhutanese have been diving into hoops just to get their bucks across borders....

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 77

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 42

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Bloomberg, HKEX Expand Offshore RMB Bond Indices

Updated Category News Views 44

A Move to Elevate Dim Sum Bonds If you're wondering what's cooking in the bond market arena, Bloomberg and HKEX just turned up the heat with a new family of RMB bond indices. These aren't just any run-of-the-mill indices; they're targeting the offshore RMB market, affectionately called the Dim Sum bond market. For those of us grizzled vets in the trading world, this is...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 416

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 258

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

VOOG's 15-Year Climb: Compounding Gains or Just a Mirage?

Updated Category News Views 255

Fifteen years back, you could have dropped $1000 into the Vanguard S&P 500 Growth ETF (NYSE:VOOG), and that cash would’ve exploded into a whopping $7,164.65 today. That’s a staggering annualized return of 14.01%, comfortably outpacing the market by about 2.35%. Sounds easy, right? But let’s peel back this seemingly golden curtain. VOOG's Performance: The Big Picture...

Continue Reading
Mercer International Inc. Faces Financial Challenges in Q2 2025

Updated Category News Views 256

Financial Overview of Mercer International Inc. for Q2 2025 Mercer International Inc. recently disclosed its financial performance for the second quarter of 2025, revealing significant challenges. The company reported an Operating EBITDA of negative $20.9 million alongside a net loss of $86.1 million, a stark contrast to the positive $30.4 million Operating EBITDA and a...

Continue Reading
EU's Strategic Response to Potential Trade Challenges with Trump

Updated Category News Views 167

EU's Trade Engagement Strategy with the New Administration The European Union is gearing up for an essential phase in its trade relations with the U.S. as Donald Trump prepares to take office once again. The EU's ministers have clearly expressed the need to foster constructive dialogue regarding trade policies while remaining vigilant about any potential tariff...

Continue Reading
Regenative Labs Casts Spotlight on Plantar Fascia Innovations

Updated Category News Views 44

Rethinking Plantar Fasciitis with Wharton’s Jelly When it comes to those of us keeping an eye on regenerative medicine, it’s like standing on the edge of a wild frontier sometimes. Today, we’ve got Regenative Labs out of Pensacola shining a light on something that’s often a real pain—literally and figuratively: plantar fasciitis. Clinical Studies with Promising...

Continue Reading
GC Biopharma's BARYCELA Secures Marketing Authorization

Updated Category News Views 171

GC Biopharma's Breakthrough with BARYCELA GC Biopharma, a prominent South Korean pharmaceutical company, has achieved a significant milestone with the recent marketing authorization of its varicella vaccine, BARYCELA, in Vietnam. This accomplishment follows earlier domestic approval and WHO Pre-Qualification, demonstrating the company’s commitment to expanding its...

Continue Reading